GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases, has announced that its Chairman and CEO, David Dodd, will present at two major investor events in September 2024. These presentations are crucial for investors and stakeholders interested in the company's advancements and strategic direction.
The first event is the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9, 2024, at the Lotte New York Palace Hotel in New York City. David Dodd will deliver a corporate update at 7:00 a.m. ET, which will be available via a webcast. This conference is an opportunity for GeoVax to engage with a broad spectrum of investors, showcasing their ongoing projects and future plans.
The second event is the Emerging Growth Conference, set for September 25, 2024, at 2:55 p.m. ET, and will be held virtually. Dodd's presentation, which will also be a corporate update, can be accessed through a webcast link. This virtual format allows for a wider audience reach, enabling potential investors globally to participate and gain insights into GeoVax's initiatives.
GeoVax's participation in these conferences is significant given the company's recent progress in its clinical programs. Notably, GeoVax's lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine, has been awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial. This trial aims to evaluate the efficacy of GEO-CM04S1 compared to an approved COVID-19 vaccine. Additionally, GEO-CM04S1 is undergoing three Phase 2 clinical trials to assess its performance as a primary vaccine for immunocompromised patients, a booster for patients with chronic lymphocytic leukemia (CLL), and as a durable COVID-19 booster for healthy individuals previously vaccinated with mRNA vaccines.
In the oncology sector, GeoVax is evaluating Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. This underscores the company's commitment to addressing critical healthcare challenges through innovative solutions. GeoVax's strong intellectual property portfolio and experienced leadership team further bolster its potential for significant advancements and value creation in the biotechnology sector.
These upcoming presentations are poised to provide valuable updates and insights into GeoVax's strategic initiatives, offering a platform to highlight their ongoing research, clinical trials, and future directions. For further details on GeoVax's clinical trials and other updates, visit their website at www.geovax.com.
